Monoclonal Gammopathy of Undetermined Cardiovascular Significance; Current Evidence and Novel Insights
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition characterized by the presence of low levels of a monoclonal protein in the serum and a low percentage of clonal plasma cells in the bone marrow. MGUS may progress to multiple myeloma or other plasma cell disorders at a rate of 1% annually. However, MGUS may also have adverse effects on the cardiovascular system independent of its malignant potential. Emerging data have shown that MGUS is associated with cardiovascular disease. The mechanisms underlying this association are not fully understood but may involve genetic abnormalities, vascular calcification, cryoglobulinemia, cold agglutinin disease, autoantibodies and the direct or indirect effects of the monoclonal protein on the vascular endothelium. Herein, we review current evidence in this field and we suggest that patients with MGUS may benefit from regular cardiovascular risk assessment to prevent severe cardiovascular complications, in parallel with close hematological follow-up to monitor potential disease progression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of cardiovascular development and disease - 10(2023), 12 vom: 04. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tentolouris, Anastasios [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiovascular disease |
|---|
| Anmerkungen: |
Date Revised 24.12.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcdd10120484 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366233122 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366233122 | ||
| 003 | DE-627 | ||
| 005 | 20231227140745.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcdd10120484 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1237.xml |
| 035 | |a (DE-627)NLM366233122 | ||
| 035 | |a (NLM)38132652 | ||
| 035 | |a (PII)484 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tentolouris, Anastasios |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Monoclonal Gammopathy of Undetermined Cardiovascular Significance; Current Evidence and Novel Insights |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition characterized by the presence of low levels of a monoclonal protein in the serum and a low percentage of clonal plasma cells in the bone marrow. MGUS may progress to multiple myeloma or other plasma cell disorders at a rate of 1% annually. However, MGUS may also have adverse effects on the cardiovascular system independent of its malignant potential. Emerging data have shown that MGUS is associated with cardiovascular disease. The mechanisms underlying this association are not fully understood but may involve genetic abnormalities, vascular calcification, cryoglobulinemia, cold agglutinin disease, autoantibodies and the direct or indirect effects of the monoclonal protein on the vascular endothelium. Herein, we review current evidence in this field and we suggest that patients with MGUS may benefit from regular cardiovascular risk assessment to prevent severe cardiovascular complications, in parallel with close hematological follow-up to monitor potential disease progression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a MGUS | |
| 650 | 4 | |a cardiovascular disease | |
| 650 | 4 | |a myocardial infarction | |
| 650 | 4 | |a peripheral arterial disease | |
| 650 | 4 | |a stroke | |
| 700 | 1 | |a Ntanasis-Stathopoulos, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Gavriatopoulou, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Andreadou, Ioanna |e verfasserin |4 aut | |
| 700 | 1 | |a Terpos, Evangelos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cardiovascular development and disease |d 2014 |g 10(2023), 12 vom: 04. Dez. |w (DE-627)NLM248446517 |x 2308-3425 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:12 |g day:04 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcdd10120484 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 12 |b 04 |c 12 | ||